For example, previous observational studies have suggested that patients prescribed statins, inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase in the mevalonate pathway, have better overall survival rates for a variety of cancers including NSCLC [43], even at late stages [44], and in patients undergoing EGFR inhibitor therapy [45]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.